Real‐world experience of tyrosine kinase inhibitors in children, adolescents and adults with relapsed or refractory bone tumours: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) study

OBJECTIVES: We conducted a retrospective multi‐centre study to assess the real‐world outcome of regorafenib (REGO) and cabozantinib (CABO) in recurrent/refractory bone tumours (BTs) including osteosarcoma (OST), Ewing sarcoma (EWS) and chondrosarcoma (CS)/extra‐skeletal mesenchymal CS (ESMC). METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Peretz Soroka, Hagit, Vora, Tushar, Noujaim, Jonathan, Marcoux, Nicolas, Cohen‐Gogo, Sarah, Alcindor, Thierry, Holloway, Caroline, Rodrigues, Caroline, Karachiwala, Hatim, Alvi, Saima, Lee, Ursula, Cheng, Sylvia, Banerji, Shantanu, Oberoi, Sapna, Feng, Xiaolan, Smrke, Alannah, Simmons, Christine, Razak, Albiruni Abdul, Gupta, Abha A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557866/
https://www.ncbi.nlm.nih.gov/pubmed/37724607
http://dx.doi.org/10.1002/cam4.6515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557866/
https://www.ncbi.nlm.nih.gov/pubmed/37724607
http://dx.doi.org/10.1002/cam4.6515

Ejemplares similares